Trends in access to anti‐malarial treatment in the formal private sector in Uganda: an assessment of availability and affordability of first‐line anti‐malarials and diagnostics between 2007 and 2018

Abstract

Background Malaria is the single largest cause of illness in Uganda. Since the year 2008, the Global Fund has rolled out several funding streams for malaria control in Uganda. Among these are mechanisms aimed at increasing the availability and affordability of artemisinin-based combination therapy (ACT). This paper examines the availability and affordability of first-line malaria treatment and diagnostics in the private sector, which is the preferred first point of contact for 61% of households in Uganda between 2007 and 2018. Methods Cross-sectional surveys were conducted between 2007 and 2018, based on a standardized World Health Organization/Health Action International (WHO/HAI) methodology adapted to assess availability, patient prices, and affordability of ACT medicines in private retail outlets. A minimum of 30 outlets were surveyed per year as prescribed by the standardized methodology co-developed by the WHO and Health Action International. Availability, patient prices, and affordability of malaria rapid diagnostic tests (RDTs) was also tracked from 2012 following the rollout of the test and treat policy in 2010. The median patient prices for the artemisinin-based combinations and RDTs was calculated in US dollars (USD). Affordability was assessed by computing the number of days’ wages the lowest-paid government worker (LPGW) had to pay to purchase a treatment course for acute malaria. Results Availability of artemether/lumefantrine (A/L), the first-line ACT medicine, increased from 85 to100% in the private sector facilities during the study period. However, there was low availability of diagnostic tests in private sector facilities ranging between 13% (2012) and 37% (2018). There was a large reduction in patient prices for an adult treatment course of A/L from USD 8.8 in 2007 to USD 1.1 in 2018, while the price of diagnostics remained mostly stagnant at USD 0.5. The affordability of ACT medicines and RDTs was below one day’s wages for LPGW. Conclusions Availability of ACT medicines in the private sector medicines retail outlets increased to 100% while the availability of diagnostics remained low. Although malaria treatment was affordable, the price of diagnostics remained stagnant and increased the cumulative cost of malaria management. Malaria stakeholders should consolidate the gains made and consider the inclusion of diagnostic kits in the subsidy programme.

Availability of malaria diagnostic tests, anti-malarial drugs, and the correctness of treatment: a systematic review and meta-analysis

“…Overall (I^2 = 83.65%, p = 0.00) Kibira [36] Abiodun [17] Mohamoud [34] Gallay [39] Aguemon [38] Garg [37] Zurovac [21] Bamiselu [41] Study Plucinski [18] Namuyinga [19] 0…”

“…Abiodun [17] Bamiselu [41] Steinhardt [44] Mohamoud [34] Kibira [36] Namuyinga [19] Zurovac 2 [21] Rowe [45] Zurovac [42] Aguemon [38] Garg [37] Plucinski […”

Adherence to malaria management guidelines by health care workers in the Busoga sub-region, eastern Uganda

“…As testing services were often available at most facilities including those where patients were not tested, reasons other than lack of RDTs or microscopy services, such as large patient volumes, could explain lack of testing at some facilities. Malaria testing rates were low at PFP (67.3%) facilities, a recognized problem of PFP facilities [ 12 , 22 – 25 ]. Ironically, all PFP had malaria test services being offered on the day of the survey, contrasting with previous studies indicating limited availability of malaria testing services at PFP facilities [ 12 ].…”

Access to quality assured artemisinin-based combination therapies and associated factors among selected private drug outlet clients in Uganda

“…Studies have reported cases where malaria patients in the private sector are not able to purchase a full dose of ACT antimalarial agent [10]. This potentially predisposes patients to inappropriate treatment practices such as taking suboptimal dose of antimalarial agents.…”